{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"retatrutide-glp1-agonists","title":"retatrutide glp1 agonists","body":"## Overview\nEvidence is being populated by Grok web search.","hero":null,"images":[],"style":{},"tags":[],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/retatrutide-glp1-agonists/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c_map_retatrutide-glp1-agonist","text":"Combinatorial mapping (transparent): retatrutide vs glp1-agonists — regen=0.38, degen=0.35, Δ=0.03. Method: layer_relevance(0.75) × evidence_factor(0.40); catalog.degen_score for GLP-1 agonists (class).","section":"what_is_known","tier":"runtime","weight":0.35,"stance_scores":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41723268/","title":"Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide ...","quote":"Our findings demonstrate that all three GLP-1 analogs, semaglutide, tirzepatide, and retatrutide , exhibit significant anti-obesity effects in MC4R KO mice.","summary":"2026 study showing anti-obesity effects of retatrutide and comparators in MC4R KO mice.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:32.443Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"d1683ea5935261c4b3e540e35123846d998a2f0c0c6857a20ee1f48c1f92ef75"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40685589/","title":"Efficacy and Safety of GLP-1 Receptor Agonists, Dual ...","quote":"Retatrutide offers superior weight loss efficacy but with a higher AE risk. Dual agonists provide a favorable efficacy-safety balance.","summary":"2025/2026 comparison of GLP-1 agonists including retatrutide on efficacy and safety.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:32.443Z","link_status":"ok","quote_status":"verified","prev":"d1683ea5935261c4b3e540e35123846d998a2f0c0c6857a20ee1f48c1f92ef75","hash":"91c54969fdb55658795ce6925aa0bf2ae4027f4b45d44462629ce8bb170f90dc"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40291085/","title":"Efficacy and safety of retatrutide, a novel GLP-1, GIP, and ...","quote":"Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.","summary":"Meta or review on retatrutide's effects in obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:32.443Z","link_status":"ok","quote_status":"verified","prev":"91c54969fdb55658795ce6925aa0bf2ae4027f4b45d44462629ce8bb170f90dc","hash":"d09058577dab1f1a5637fdc7e29607acc03e770cbb22bce0592ec02b2683a707"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40563436/","title":"Retatrutide-A Game Changer in Obesity Pharmacotherapy","quote":"Retatrutide's unique molecular structure enables potent activation of GLP - 1 , GIP, and glucagon receptors, leading to significant weight reduction, improved ...","summary":"2025 review highlighting retatrutide as triple agonist for obesity and T2DM.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:32.443Z","link_status":"ok","quote_status":"unverified","prev":"d09058577dab1f1a5637fdc7e29607acc03e770cbb22bce0592ec02b2683a707","hash":"d6970f615871708696a0f4b689dfe2e2a22e19a67f6608b3d4909e70083e8318"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT05882045","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)","quote":"The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD).","summary":"Ongoing phase 3 trial on retatrutide for obesity with CVD.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:32.443Z","link_status":"ok","quote_status":"unverified","prev":"d6970f615871708696a0f4b689dfe2e2a22e19a67f6608b3d4909e70083e8318","hash":"71b2363f74d8cdb08d52eabe603f162d7ac5b04e990aab785ebd502c2ed9598a"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/","title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes... (TRANSCEND-T2D-1)","quote":"Retatrutide showed significant ... Two deaths occurred during the study , both in the retatrutide 4 mg group and unrelated to the study drug.","summary":"2026 phase 3 trial results in T2D patients.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:32.443Z","link_status":"ok","quote_status":"unverified","prev":"71b2363f74d8cdb08d52eabe603f162d7ac5b04e990aab785ebd502c2ed9598a","hash":"07fd561d3e724bd7289bd9fc8c9ba65b293ebc3aaafd5e25aa0b08f276df9bb6"},{"id":"s7","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41785010/","title":"Retatrutide in type 2 diabetes mellitus and obesity: an overview","quote":"Retatrutide (LY3437943) is a novel triple agonist targeting glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1 R).","summary":"2026 review on retatrutide for T2DM and obesity, noting significant weight loss up to 16.94% in T2DM subjects.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:51.054Z","link_status":"ok","quote_status":"verified","prev":"07fd561d3e724bd7289bd9fc8c9ba65b293ebc3aaafd5e25aa0b08f276df9bb6","hash":"0413b2dceecc121c9344f2393b120dc7bd4fa130f2536018d65985efa23a0638"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41545327/","title":"Retatrutide and the Paradigm Shift in Multi-Hormonal ...","quote":"Retatrutide (LY3437943), a novel triple agonist targeting GLP-1, glucose-dependent represents a transformative advance in obesity pharmacotherapy.","summary":"2026 PubMed article on retatrutide as a triple agonist for obesity treatment.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:51.054Z","link_status":"ok","quote_status":"unverified","prev":"0413b2dceecc121c9344f2393b120dc7bd4fa130f2536018d65985efa23a0638","hash":"520b95b711b028b7bba17be154a2028bcbb775dbad63438aa8b1382346687c4a"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42135195/","title":"Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes","quote":"retatrutide reduced body weight, hemoglobin A1c, and improved the lipid profiles of participants living with obesity, with and without T2D.","summary":"2026 study on retatrutide's effects on lipids and metabolites in obesity/T2D.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:51.054Z","link_status":"ok","quote_status":"verified","prev":"520b95b711b028b7bba17be154a2028bcbb775dbad63438aa8b1382346687c4a","hash":"1192147733cc9b9d62d25d617cee59c3c9654dd609e3b3714b1644fead9b822c"},{"id":"s10","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/42108533/","title":"Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review","quote":"Retatrutide is a first-in-class, unimolecular triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors.","summary":"2026 comprehensive review on retatrutide for CKM syndrome, including liver disease benefits.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:51.054Z","link_status":"ok","quote_status":"verified","prev":"1192147733cc9b9d62d25d617cee59c3c9654dd609e3b3714b1644fead9b822c","hash":"be593910255a4e73aa5237dc56b68903b46dea4c7877f8444343861e8b80a3fb"},{"id":"s11","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41741376/","title":"Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models","quote":"Retatrutide markedly reduced the HOMA-IR index of insulin resistance , hepatic steatosis score, fatty acids, triglycerides, and total cholesterol content.","summary":"2026 preclinical study on metabolic benefits of retatrutide in MASH models.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:51.054Z","link_status":"ok","quote_status":"unverified","prev":"be593910255a4e73aa5237dc56b68903b46dea4c7877f8444343861e8b80a3fb","hash":"b61d2944fb0e25dd65626d2748f78786b7b07a05bcd52bf90dfcef892ca3d37e"},{"id":"s12","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07232719","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)","quote":"The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.","summary":"New 2026 Phase 3 trial NCT07232719 for retatrutide in obesity/overweight.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:51.054Z","link_status":"ok","quote_status":"unverified","prev":"b61d2944fb0e25dd65626d2748f78786b7b07a05bcd52bf90dfcef892ca3d37e","hash":"40117b02abb718facc077b7e51c3e1660ac4fe195db35a0ca87e1b635f2a215f"},{"id":"s13","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06662383","title":"A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)","quote":"The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity.","summary":"New Phase 3 trial comparing retatrutide to tirzepatide in obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:51.054Z","link_status":"ok","quote_status":"unverified","prev":"40117b02abb718facc077b7e51c3e1660ac4fe195db35a0ca87e1b635f2a215f","hash":"1a0ff0178209f4d93e297f0e32fcf31038b10a0ae6c312c65bbe05f8fa3313e5"},{"id":"s14","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39724554/","title":"The First Triple Agonist for Antiobesity: Retatrutide","quote":"One such drug is retatrutide , which is a triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent ...","summary":"Overview of retatrutide as the first triple agonist for antiobesity treatment.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"unverified","prev":"1a0ff0178209f4d93e297f0e32fcf31038b10a0ae6c312c65bbe05f8fa3313e5","hash":"692b8380b96c0c329e96f5ea6fd314bc5c42c72bfd5e27a03e60e48dae0a2426"},{"id":"s15","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38858523/","title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","quote":"Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors.","summary":"Phase 2a trial results on retatrutide for MASLD.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"verified","prev":"692b8380b96c0c329e96f5ea6fd314bc5c42c72bfd5e27a03e60e48dae0a2426","hash":"bfd3b1ac48a7c655f2a968392b509ee68badc63b0411a37ccf04dd66db63bbbd"},{"id":"s16","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","title":"Effects of retatrutide on body composition in people with type 2 diabetes","quote":"In adults with type 2 diabetes, retatrutide significantly improved total body fat mass reduction compared with placebo and dulaglutide.","summary":"Body composition improvements with retatrutide in T2D patients.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"verified","prev":"bfd3b1ac48a7c655f2a968392b509ee68badc63b0411a37ccf04dd66db63bbbd","hash":"047c02d60235f2bf0487e91da1b36eb6dfdeb28aea035608517e56127520d5c7"},{"id":"s17","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41090431/","title":"Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials","quote":"Retatrutide , a novel synthetic molecule, is a triple agonist activating the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors.","summary":"Design of TRIUMPH trials for retatrutide in multiple conditions.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"unverified","prev":"047c02d60235f2bf0487e91da1b36eb6dfdeb28aea035608517e56127520d5c7","hash":"a8ebd7ce7d6aab63b1862a9e8f93d6871e39cdf0450ad7ed20ae67e1851ecd98"},{"id":"s18","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39817343/","title":"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis","quote":"Retatrutide is a novel triple hormone receptor agonist which has shown great promise in tackling obesity in preliminary trials.","summary":"Meta-analysis of retatrutide efficacy and safety for obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"verified","prev":"a8ebd7ce7d6aab63b1862a9e8f93d6871e39cdf0450ad7ed20ae67e1851ecd98","hash":"f625da21766730da1a65bf19e0c5f88b06a63deed365473aa280efe4ff3d5f7b"},{"id":"s19","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40094000/","title":"Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression","quote":"Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression","summary":"Preclinical evidence on retatrutide reducing obesity-linked cancer progression.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"verified","prev":"f625da21766730da1a65bf19e0c5f88b06a63deed365473aa280efe4ff3d5f7b","hash":"c1dbf6e8363dc6087f7f304af384691a9f3f9c4472b8fd4ebb7cf05b1c7e0a35"},{"id":"s20","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40741227/","title":"Triple Agonism Based Therapies for Obesity","quote":"... retatrutide , the most advanced candidate. Recent findings: Retatrutide is the first triple agonist (acting on GLP-1 /GIP/glucagon receptors) ...","summary":"Review of triple agonist therapies including retatrutide.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"unverified","prev":"c1dbf6e8363dc6087f7f304af384691a9f3f9c4472b8fd4ebb7cf05b1c7e0a35","hash":"215a294f2347346cadf1f7d3581dac220724015f5931db72b5ca0f1bcf0e0c18"},{"id":"s21","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT05936151","title":"A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes","quote":"The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D).","summary":"Phase 2b trial on retatrutide effects on renal function in CKD.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"unverified","prev":"215a294f2347346cadf1f7d3581dac220724015f5931db72b5ca0f1bcf0e0c18","hash":"f05e2935b943923a4fc0d1dc3cd87e384a11f81681ebb2532c9478a221e6b0ab"},{"id":"s22","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT05931367","title":"A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee","quote":"The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or overweight and have osteoarthritis (OA) of the knee.","summary":"Phase 3 TRIUMPH-4 trial for retatrutide in OA patients.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"unverified","prev":"f05e2935b943923a4fc0d1dc3cd87e384a11f81681ebb2532c9478a221e6b0ab","hash":"7b99e640159338e308c04066e2fe3d7e3d6e5cfb32c207a1f5a1093795e6ce4a"}],"reviews":[],"extra":{},"has_traversal":false,"register":"standard","status":"published","revisions":3,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T17:43:16.338Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"retatrutide glp1 agonists","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"99da3efa4b840b5d74174858a41451496af4269704696c2ad8a0074d454a9766"},{"seq":1,"id":"k2","ts":"2026-06-29T17:43:33.110Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41723268/","title":"Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide ...","quote":"Our findings demonstrate that all three GLP-1 analogs, semaglutide, tirzepatide, and retatrutide , exhibit significant anti-obesity effects in MC4R KO mice.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40685589/","title":"Efficacy and Safety of GLP-1 Receptor Agonists, Dual ...","quote":"Retatrutide offers superior weight loss efficacy but with a higher AE risk. Dual agonists provide a favorable efficacy-safety balance.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40291085/","title":"Efficacy and safety of retatrutide, a novel GLP-1, GIP, and ...","quote":"Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40563436/","title":"Retatrutide-A Game Changer in Obesity Pharmacotherapy","quote":"Retatrutide's unique molecular structure enables potent activation of GLP - 1 , GIP, and glucagon receptors, leading to significant weight reduction, improved ...","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT05882045","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)","quote":"The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD).","link_status":"ok","quote_status":"unverified"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/","title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes... (TRANSCEND-T2D-1)","quote":"Retatrutide showed significant ... Two deaths occurred during the study , both in the retatrutide 4 mg group and unrelated to the study drug.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"99da3efa4b840b5d74174858a41451496af4269704696c2ad8a0074d454a9766","hash":"33d1e58e3c56f03a7c33413fd9f54e56c9d4f0077025e390548424349dad7b01"},{"seq":2,"id":"k3","ts":"2026-06-29T17:43:51.697Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s7","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41785010/","title":"Retatrutide in type 2 diabetes mellitus and obesity: an overview","quote":"Retatrutide (LY3437943) is a novel triple agonist targeting glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1 R).","link_status":"ok","quote_status":"verified"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41545327/","title":"Retatrutide and the Paradigm Shift in Multi-Hormonal ...","quote":"Retatrutide (LY3437943), a novel triple agonist targeting GLP-1, glucose-dependent represents a transformative advance in obesity pharmacotherapy.","link_status":"ok","quote_status":"unverified"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42135195/","title":"Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes","quote":"retatrutide reduced body weight, hemoglobin A1c, and improved the lipid profiles of participants living with obesity, with and without T2D.","link_status":"ok","quote_status":"verified"},{"id":"s10","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/42108533/","title":"Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review","quote":"Retatrutide is a first-in-class, unimolecular triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors.","link_status":"ok","quote_status":"verified"},{"id":"s11","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41741376/","title":"Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models","quote":"Retatrutide markedly reduced the HOMA-IR index of insulin resistance , hepatic steatosis score, fatty acids, triglycerides, and total cholesterol content.","link_status":"ok","quote_status":"unverified"},{"id":"s12","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07232719","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)","quote":"The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.","link_status":"ok","quote_status":"unverified"},{"id":"s13","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06662383","title":"A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)","quote":"The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"33d1e58e3c56f03a7c33413fd9f54e56c9d4f0077025e390548424349dad7b01","hash":"a44f9e7083c7b500eb82ef017927dc60d4dceeee4c253515a917c1c40dd0ddf5"},{"seq":3,"id":"k4","ts":"2026-06-29T17:44:38.125Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s14","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39724554/","title":"The First Triple Agonist for Antiobesity: Retatrutide","quote":"One such drug is retatrutide , which is a triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent ...","link_status":"ok","quote_status":"unverified"},{"id":"s15","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38858523/","title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","quote":"Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors.","link_status":"ok","quote_status":"verified"},{"id":"s16","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","title":"Effects of retatrutide on body composition in people with type 2 diabetes","quote":"In adults with type 2 diabetes, retatrutide significantly improved total body fat mass reduction compared with placebo and dulaglutide.","link_status":"ok","quote_status":"verified"},{"id":"s17","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41090431/","title":"Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials","quote":"Retatrutide , a novel synthetic molecule, is a triple agonist activating the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors.","link_status":"ok","quote_status":"unverified"},{"id":"s18","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39817343/","title":"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis","quote":"Retatrutide is a novel triple hormone receptor agonist which has shown great promise in tackling obesity in preliminary trials.","link_status":"ok","quote_status":"verified"},{"id":"s19","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40094000/","title":"Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression","quote":"Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression","link_status":"ok","quote_status":"verified"},{"id":"s20","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40741227/","title":"Triple Agonism Based Therapies for Obesity","quote":"... retatrutide , the most advanced candidate. Recent findings: Retatrutide is the first triple agonist (acting on GLP-1 /GIP/glucagon receptors) ...","link_status":"ok","quote_status":"unverified"},{"id":"s21","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT05936151","title":"A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes","quote":"The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D).","link_status":"ok","quote_status":"unverified"},{"id":"s22","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT05931367","title":"A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee","quote":"The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or overweight and have osteoarthritis (OA) of the knee.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"a44f9e7083c7b500eb82ef017927dc60d4dceeee4c253515a917c1c40dd0ddf5","hash":"c173a01bf5f944daafc3a964d4f12c2ecfb6d704c9a6327cc11c22ca3c025260"}],"provenance":[{"ts":"2026-06-29T17:43:16.338Z","model":"grok-4.3","action":"populate-init","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"151871128c7363f142a48163c2396a46abf5b9d86640211b59aa197b84bc859c"},{"ts":"2026-06-29T17:43:33.110Z","model":"grok-4.3","action":"sources","prompt":"","input":"retatrutide-glp1-agonists","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"151871128c7363f142a48163c2396a46abf5b9d86640211b59aa197b84bc859c","hash":"f8d8e9c0b6406f55e6290e0349b8d5b3f1703e592b8029c90cdb898b88e5f64f"},{"ts":"2026-06-29T17:43:51.697Z","model":"grok-4.3","action":"sources","prompt":"","input":"retatrutide-glp1-agonists","response":"7 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f8d8e9c0b6406f55e6290e0349b8d5b3f1703e592b8029c90cdb898b88e5f64f","hash":"4632ae98b947445370780b0b55eb535f5b6d8c5c69d4f3b46ab5737788381b1e"},{"ts":"2026-06-29T17:44:38.125Z","model":"grok-4.3","action":"sources","prompt":"","input":"retatrutide-glp1-agonists","response":"9 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4632ae98b947445370780b0b55eb535f5b6d8c5c69d4f3b46ab5737788381b1e","hash":"9878468bd5aea011d19f397acbd61091f3e38e6b15582992c8baab1421cefea3"},{"ts":"2026-07-17T02:41:16.988Z","model":"owner","action":"voxel_divide","prompt":"","input":"retatrutide-glp1-agonists","response":"2 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9878468bd5aea011d19f397acbd61091f3e38e6b15582992c8baab1421cefea3","hash":"f2edce16f0ccad986a0539d48958cf9f9a1110c48065174897c92de441f45e7a"}],"energy":{"passes":5,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"grok-4.3":4,"owner":1},"head":"f2edce16f0ccad986a0539d48958cf9f9a1110c48065174897c92de441f45e7a"},"posted_at":"2026-06-29T17:43:16.338Z","created_at":"2026-06-29T17:43:16.338Z","updated_at":"2026-07-17T02:41:16.988Z","machine":{"shape":"article.machine/v1","slug":"retatrutide-glp1-agonists","kind":"article","read":{"human":"https://miscsubjects.com/a/retatrutide-glp1-agonists","json":"https://miscsubjects.com/api/articles/retatrutide-glp1-agonists","bundle":"https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":1,"sources":22,"contributions":4,"revisions":3,"objections_url":"https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=retatrutide-glp1-agonists","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-glp1-agonists\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-glp1-agonists\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"retatrutide-glp1-agonists\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/retatrutide-glp1-agonists | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/retatrutide-glp1-agonists","json":"/api/articles/retatrutide-glp1-agonists","markdown":"/api/articles/retatrutide-glp1-agonists/bundle?format=markdown","skill":"/api/articles/retatrutide-glp1-agonists/skill","topology":"/api/articles/retatrutide-glp1-agonists/topology","versions":"/api/articles/retatrutide-glp1-agonists/revisions","invocations":"/api/articles/retatrutide-glp1-agonists/invocations"},"editorial_review":null,"editorial_audit":{"slug":"retatrutide-glp1-agonists","ok":false,"issues":[{"code":"heading_filing_label","message":"section heading “Overview” is a filing label that gives a cold reader no claim","replacement":"Replace “Overview” with the concrete claim, event, or object introduced in that section."},{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"dcd6b7bdb3704e6e308dd7c9e774bd45269f7b4d7d44b04b150e3024d021c061","object":{"object_type":"article-object","identity":{"id":"article:retatrutide-glp1-agonists","slug":"retatrutide-glp1-agonists","title":"retatrutide glp1 agonists"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/retatrutide-glp1-agonists","role":"explain","audience":"human"},"skill":{"route":"/api/articles/retatrutide-glp1-agonists/skill","role":"direct behavior","audience":"model","content":"---\nname: retatrutide-glp1-agonists\ndescription: Apply the retatrutide glp1 agonists article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# retatrutide glp1 agonists\n\nThis Skill is the behavioral expression of [the canonical article](/a/retatrutide-glp1-agonists). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/retatrutide-glp1-agonists.\n- Read claims and relationships at /api/articles/retatrutide-glp1-agonists/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nOverview Evidence is being populated by Grok web search.\n\n## Representations\n\n- Human: /a/retatrutide-glp1-agonists\n- JSON: /api/articles/retatrutide-glp1-agonists\n- Relationships: /api/articles/retatrutide-glp1-agonists/topology\n- History: /api/articles/retatrutide-glp1-agonists/revisions\n"},"json":{"route":"/api/articles/retatrutide-glp1-agonists","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/retatrutide-glp1-agonists/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["retatrutide","glp1","agonists"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/retatrutide-glp1-agonists/invocations?status=success","failure_events":"/api/articles/retatrutide-glp1-agonists/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"retatrutide-glp1-agonists","title":"retatrutide glp1 agonists","body":"## Overview\nEvidence is being populated by Grok web search.","hero":null,"images":[],"style":{},"tags":[],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/retatrutide-glp1-agonists/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c_map_retatrutide-glp1-agonist","text":"Combinatorial mapping (transparent): retatrutide vs glp1-agonists — regen=0.38, degen=0.35, Δ=0.03. Method: layer_relevance(0.75) × evidence_factor(0.40); catalog.degen_score for GLP-1 agonists (class).","section":"what_is_known","tier":"runtime","weight":0.35,"stance_scores":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41723268/","title":"Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide ...","quote":"Our findings demonstrate that all three GLP-1 analogs, semaglutide, tirzepatide, and retatrutide , exhibit significant anti-obesity effects in MC4R KO mice.","summary":"2026 study showing anti-obesity effects of retatrutide and comparators in MC4R KO mice.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:32.443Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"d1683ea5935261c4b3e540e35123846d998a2f0c0c6857a20ee1f48c1f92ef75"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40685589/","title":"Efficacy and Safety of GLP-1 Receptor Agonists, Dual ...","quote":"Retatrutide offers superior weight loss efficacy but with a higher AE risk. Dual agonists provide a favorable efficacy-safety balance.","summary":"2025/2026 comparison of GLP-1 agonists including retatrutide on efficacy and safety.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:32.443Z","link_status":"ok","quote_status":"verified","prev":"d1683ea5935261c4b3e540e35123846d998a2f0c0c6857a20ee1f48c1f92ef75","hash":"91c54969fdb55658795ce6925aa0bf2ae4027f4b45d44462629ce8bb170f90dc"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40291085/","title":"Efficacy and safety of retatrutide, a novel GLP-1, GIP, and ...","quote":"Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.","summary":"Meta or review on retatrutide's effects in obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:32.443Z","link_status":"ok","quote_status":"verified","prev":"91c54969fdb55658795ce6925aa0bf2ae4027f4b45d44462629ce8bb170f90dc","hash":"d09058577dab1f1a5637fdc7e29607acc03e770cbb22bce0592ec02b2683a707"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40563436/","title":"Retatrutide-A Game Changer in Obesity Pharmacotherapy","quote":"Retatrutide's unique molecular structure enables potent activation of GLP - 1 , GIP, and glucagon receptors, leading to significant weight reduction, improved ...","summary":"2025 review highlighting retatrutide as triple agonist for obesity and T2DM.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:32.443Z","link_status":"ok","quote_status":"unverified","prev":"d09058577dab1f1a5637fdc7e29607acc03e770cbb22bce0592ec02b2683a707","hash":"d6970f615871708696a0f4b689dfe2e2a22e19a67f6608b3d4909e70083e8318"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT05882045","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)","quote":"The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD).","summary":"Ongoing phase 3 trial on retatrutide for obesity with CVD.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:32.443Z","link_status":"ok","quote_status":"unverified","prev":"d6970f615871708696a0f4b689dfe2e2a22e19a67f6608b3d4909e70083e8318","hash":"71b2363f74d8cdb08d52eabe603f162d7ac5b04e990aab785ebd502c2ed9598a"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/","title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes... (TRANSCEND-T2D-1)","quote":"Retatrutide showed significant ... Two deaths occurred during the study , both in the retatrutide 4 mg group and unrelated to the study drug.","summary":"2026 phase 3 trial results in T2D patients.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:32.443Z","link_status":"ok","quote_status":"unverified","prev":"71b2363f74d8cdb08d52eabe603f162d7ac5b04e990aab785ebd502c2ed9598a","hash":"07fd561d3e724bd7289bd9fc8c9ba65b293ebc3aaafd5e25aa0b08f276df9bb6"},{"id":"s7","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41785010/","title":"Retatrutide in type 2 diabetes mellitus and obesity: an overview","quote":"Retatrutide (LY3437943) is a novel triple agonist targeting glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1 R).","summary":"2026 review on retatrutide for T2DM and obesity, noting significant weight loss up to 16.94% in T2DM subjects.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:51.054Z","link_status":"ok","quote_status":"verified","prev":"07fd561d3e724bd7289bd9fc8c9ba65b293ebc3aaafd5e25aa0b08f276df9bb6","hash":"0413b2dceecc121c9344f2393b120dc7bd4fa130f2536018d65985efa23a0638"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41545327/","title":"Retatrutide and the Paradigm Shift in Multi-Hormonal ...","quote":"Retatrutide (LY3437943), a novel triple agonist targeting GLP-1, glucose-dependent represents a transformative advance in obesity pharmacotherapy.","summary":"2026 PubMed article on retatrutide as a triple agonist for obesity treatment.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:51.054Z","link_status":"ok","quote_status":"unverified","prev":"0413b2dceecc121c9344f2393b120dc7bd4fa130f2536018d65985efa23a0638","hash":"520b95b711b028b7bba17be154a2028bcbb775dbad63438aa8b1382346687c4a"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42135195/","title":"Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes","quote":"retatrutide reduced body weight, hemoglobin A1c, and improved the lipid profiles of participants living with obesity, with and without T2D.","summary":"2026 study on retatrutide's effects on lipids and metabolites in obesity/T2D.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:51.054Z","link_status":"ok","quote_status":"verified","prev":"520b95b711b028b7bba17be154a2028bcbb775dbad63438aa8b1382346687c4a","hash":"1192147733cc9b9d62d25d617cee59c3c9654dd609e3b3714b1644fead9b822c"},{"id":"s10","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/42108533/","title":"Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review","quote":"Retatrutide is a first-in-class, unimolecular triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors.","summary":"2026 comprehensive review on retatrutide for CKM syndrome, including liver disease benefits.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:51.054Z","link_status":"ok","quote_status":"verified","prev":"1192147733cc9b9d62d25d617cee59c3c9654dd609e3b3714b1644fead9b822c","hash":"be593910255a4e73aa5237dc56b68903b46dea4c7877f8444343861e8b80a3fb"},{"id":"s11","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41741376/","title":"Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models","quote":"Retatrutide markedly reduced the HOMA-IR index of insulin resistance , hepatic steatosis score, fatty acids, triglycerides, and total cholesterol content.","summary":"2026 preclinical study on metabolic benefits of retatrutide in MASH models.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:51.054Z","link_status":"ok","quote_status":"unverified","prev":"be593910255a4e73aa5237dc56b68903b46dea4c7877f8444343861e8b80a3fb","hash":"b61d2944fb0e25dd65626d2748f78786b7b07a05bcd52bf90dfcef892ca3d37e"},{"id":"s12","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07232719","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)","quote":"The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.","summary":"New 2026 Phase 3 trial NCT07232719 for retatrutide in obesity/overweight.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:51.054Z","link_status":"ok","quote_status":"unverified","prev":"b61d2944fb0e25dd65626d2748f78786b7b07a05bcd52bf90dfcef892ca3d37e","hash":"40117b02abb718facc077b7e51c3e1660ac4fe195db35a0ca87e1b635f2a215f"},{"id":"s13","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06662383","title":"A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)","quote":"The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity.","summary":"New Phase 3 trial comparing retatrutide to tirzepatide in obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:43:51.054Z","link_status":"ok","quote_status":"unverified","prev":"40117b02abb718facc077b7e51c3e1660ac4fe195db35a0ca87e1b635f2a215f","hash":"1a0ff0178209f4d93e297f0e32fcf31038b10a0ae6c312c65bbe05f8fa3313e5"},{"id":"s14","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39724554/","title":"The First Triple Agonist for Antiobesity: Retatrutide","quote":"One such drug is retatrutide , which is a triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent ...","summary":"Overview of retatrutide as the first triple agonist for antiobesity treatment.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"unverified","prev":"1a0ff0178209f4d93e297f0e32fcf31038b10a0ae6c312c65bbe05f8fa3313e5","hash":"692b8380b96c0c329e96f5ea6fd314bc5c42c72bfd5e27a03e60e48dae0a2426"},{"id":"s15","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38858523/","title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","quote":"Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors.","summary":"Phase 2a trial results on retatrutide for MASLD.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"verified","prev":"692b8380b96c0c329e96f5ea6fd314bc5c42c72bfd5e27a03e60e48dae0a2426","hash":"bfd3b1ac48a7c655f2a968392b509ee68badc63b0411a37ccf04dd66db63bbbd"},{"id":"s16","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","title":"Effects of retatrutide on body composition in people with type 2 diabetes","quote":"In adults with type 2 diabetes, retatrutide significantly improved total body fat mass reduction compared with placebo and dulaglutide.","summary":"Body composition improvements with retatrutide in T2D patients.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"verified","prev":"bfd3b1ac48a7c655f2a968392b509ee68badc63b0411a37ccf04dd66db63bbbd","hash":"047c02d60235f2bf0487e91da1b36eb6dfdeb28aea035608517e56127520d5c7"},{"id":"s17","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41090431/","title":"Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials","quote":"Retatrutide , a novel synthetic molecule, is a triple agonist activating the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors.","summary":"Design of TRIUMPH trials for retatrutide in multiple conditions.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"unverified","prev":"047c02d60235f2bf0487e91da1b36eb6dfdeb28aea035608517e56127520d5c7","hash":"a8ebd7ce7d6aab63b1862a9e8f93d6871e39cdf0450ad7ed20ae67e1851ecd98"},{"id":"s18","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39817343/","title":"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis","quote":"Retatrutide is a novel triple hormone receptor agonist which has shown great promise in tackling obesity in preliminary trials.","summary":"Meta-analysis of retatrutide efficacy and safety for obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"verified","prev":"a8ebd7ce7d6aab63b1862a9e8f93d6871e39cdf0450ad7ed20ae67e1851ecd98","hash":"f625da21766730da1a65bf19e0c5f88b06a63deed365473aa280efe4ff3d5f7b"},{"id":"s19","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40094000/","title":"Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression","quote":"Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression","summary":"Preclinical evidence on retatrutide reducing obesity-linked cancer progression.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"verified","prev":"f625da21766730da1a65bf19e0c5f88b06a63deed365473aa280efe4ff3d5f7b","hash":"c1dbf6e8363dc6087f7f304af384691a9f3f9c4472b8fd4ebb7cf05b1c7e0a35"},{"id":"s20","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40741227/","title":"Triple Agonism Based Therapies for Obesity","quote":"... retatrutide , the most advanced candidate. Recent findings: Retatrutide is the first triple agonist (acting on GLP-1 /GIP/glucagon receptors) ...","summary":"Review of triple agonist therapies including retatrutide.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"unverified","prev":"c1dbf6e8363dc6087f7f304af384691a9f3f9c4472b8fd4ebb7cf05b1c7e0a35","hash":"215a294f2347346cadf1f7d3581dac220724015f5931db72b5ca0f1bcf0e0c18"},{"id":"s21","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT05936151","title":"A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes","quote":"The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D).","summary":"Phase 2b trial on retatrutide effects on renal function in CKD.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"unverified","prev":"215a294f2347346cadf1f7d3581dac220724015f5931db72b5ca0f1bcf0e0c18","hash":"f05e2935b943923a4fc0d1dc3cd87e384a11f81681ebb2532c9478a221e6b0ab"},{"id":"s22","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT05931367","title":"A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee","quote":"The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or overweight and have osteoarthritis (OA) of the knee.","summary":"Phase 3 TRIUMPH-4 trial for retatrutide in OA patients.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:44:37.039Z","link_status":"ok","quote_status":"unverified","prev":"f05e2935b943923a4fc0d1dc3cd87e384a11f81681ebb2532c9478a221e6b0ab","hash":"7b99e640159338e308c04066e2fe3d7e3d6e5cfb32c207a1f5a1093795e6ce4a"}],"reviews":[],"extra":{},"has_traversal":false,"register":"standard","status":"published","revisions":3,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T17:43:16.338Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"retatrutide glp1 agonists","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"99da3efa4b840b5d74174858a41451496af4269704696c2ad8a0074d454a9766"},{"seq":1,"id":"k2","ts":"2026-06-29T17:43:33.110Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41723268/","title":"Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide ...","quote":"Our findings demonstrate that all three GLP-1 analogs, semaglutide, tirzepatide, and retatrutide , exhibit significant anti-obesity effects in MC4R KO mice.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40685589/","title":"Efficacy and Safety of GLP-1 Receptor Agonists, Dual ...","quote":"Retatrutide offers superior weight loss efficacy but with a higher AE risk. Dual agonists provide a favorable efficacy-safety balance.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40291085/","title":"Efficacy and safety of retatrutide, a novel GLP-1, GIP, and ...","quote":"Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40563436/","title":"Retatrutide-A Game Changer in Obesity Pharmacotherapy","quote":"Retatrutide's unique molecular structure enables potent activation of GLP - 1 , GIP, and glucagon receptors, leading to significant weight reduction, improved ...","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT05882045","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)","quote":"The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD).","link_status":"ok","quote_status":"unverified"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/","title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes... (TRANSCEND-T2D-1)","quote":"Retatrutide showed significant ... Two deaths occurred during the study , both in the retatrutide 4 mg group and unrelated to the study drug.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"99da3efa4b840b5d74174858a41451496af4269704696c2ad8a0074d454a9766","hash":"33d1e58e3c56f03a7c33413fd9f54e56c9d4f0077025e390548424349dad7b01"},{"seq":2,"id":"k3","ts":"2026-06-29T17:43:51.697Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s7","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41785010/","title":"Retatrutide in type 2 diabetes mellitus and obesity: an overview","quote":"Retatrutide (LY3437943) is a novel triple agonist targeting glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1 R).","link_status":"ok","quote_status":"verified"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41545327/","title":"Retatrutide and the Paradigm Shift in Multi-Hormonal ...","quote":"Retatrutide (LY3437943), a novel triple agonist targeting GLP-1, glucose-dependent represents a transformative advance in obesity pharmacotherapy.","link_status":"ok","quote_status":"unverified"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42135195/","title":"Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes","quote":"retatrutide reduced body weight, hemoglobin A1c, and improved the lipid profiles of participants living with obesity, with and without T2D.","link_status":"ok","quote_status":"verified"},{"id":"s10","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/42108533/","title":"Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review","quote":"Retatrutide is a first-in-class, unimolecular triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors.","link_status":"ok","quote_status":"verified"},{"id":"s11","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41741376/","title":"Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models","quote":"Retatrutide markedly reduced the HOMA-IR index of insulin resistance , hepatic steatosis score, fatty acids, triglycerides, and total cholesterol content.","link_status":"ok","quote_status":"unverified"},{"id":"s12","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07232719","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)","quote":"The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.","link_status":"ok","quote_status":"unverified"},{"id":"s13","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06662383","title":"A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)","quote":"The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"33d1e58e3c56f03a7c33413fd9f54e56c9d4f0077025e390548424349dad7b01","hash":"a44f9e7083c7b500eb82ef017927dc60d4dceeee4c253515a917c1c40dd0ddf5"},{"seq":3,"id":"k4","ts":"2026-06-29T17:44:38.125Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s14","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39724554/","title":"The First Triple Agonist for Antiobesity: Retatrutide","quote":"One such drug is retatrutide , which is a triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent ...","link_status":"ok","quote_status":"unverified"},{"id":"s15","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38858523/","title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","quote":"Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors.","link_status":"ok","quote_status":"verified"},{"id":"s16","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","title":"Effects of retatrutide on body composition in people with type 2 diabetes","quote":"In adults with type 2 diabetes, retatrutide significantly improved total body fat mass reduction compared with placebo and dulaglutide.","link_status":"ok","quote_status":"verified"},{"id":"s17","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41090431/","title":"Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials","quote":"Retatrutide , a novel synthetic molecule, is a triple agonist activating the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors.","link_status":"ok","quote_status":"unverified"},{"id":"s18","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39817343/","title":"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis","quote":"Retatrutide is a novel triple hormone receptor agonist which has shown great promise in tackling obesity in preliminary trials.","link_status":"ok","quote_status":"verified"},{"id":"s19","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40094000/","title":"Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression","quote":"Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression","link_status":"ok","quote_status":"verified"},{"id":"s20","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40741227/","title":"Triple Agonism Based Therapies for Obesity","quote":"... retatrutide , the most advanced candidate. Recent findings: Retatrutide is the first triple agonist (acting on GLP-1 /GIP/glucagon receptors) ...","link_status":"ok","quote_status":"unverified"},{"id":"s21","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT05936151","title":"A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes","quote":"The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D).","link_status":"ok","quote_status":"unverified"},{"id":"s22","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT05931367","title":"A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee","quote":"The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or overweight and have osteoarthritis (OA) of the knee.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"a44f9e7083c7b500eb82ef017927dc60d4dceeee4c253515a917c1c40dd0ddf5","hash":"c173a01bf5f944daafc3a964d4f12c2ecfb6d704c9a6327cc11c22ca3c025260"}],"provenance":[{"ts":"2026-06-29T17:43:16.338Z","model":"grok-4.3","action":"populate-init","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"151871128c7363f142a48163c2396a46abf5b9d86640211b59aa197b84bc859c"},{"ts":"2026-06-29T17:43:33.110Z","model":"grok-4.3","action":"sources","prompt":"","input":"retatrutide-glp1-agonists","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"151871128c7363f142a48163c2396a46abf5b9d86640211b59aa197b84bc859c","hash":"f8d8e9c0b6406f55e6290e0349b8d5b3f1703e592b8029c90cdb898b88e5f64f"},{"ts":"2026-06-29T17:43:51.697Z","model":"grok-4.3","action":"sources","prompt":"","input":"retatrutide-glp1-agonists","response":"7 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f8d8e9c0b6406f55e6290e0349b8d5b3f1703e592b8029c90cdb898b88e5f64f","hash":"4632ae98b947445370780b0b55eb535f5b6d8c5c69d4f3b46ab5737788381b1e"},{"ts":"2026-06-29T17:44:38.125Z","model":"grok-4.3","action":"sources","prompt":"","input":"retatrutide-glp1-agonists","response":"9 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4632ae98b947445370780b0b55eb535f5b6d8c5c69d4f3b46ab5737788381b1e","hash":"9878468bd5aea011d19f397acbd61091f3e38e6b15582992c8baab1421cefea3"},{"ts":"2026-07-17T02:41:16.988Z","model":"owner","action":"voxel_divide","prompt":"","input":"retatrutide-glp1-agonists","response":"2 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9878468bd5aea011d19f397acbd61091f3e38e6b15582992c8baab1421cefea3","hash":"f2edce16f0ccad986a0539d48958cf9f9a1110c48065174897c92de441f45e7a"}],"energy":{"passes":5,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"grok-4.3":4,"owner":1},"head":"f2edce16f0ccad986a0539d48958cf9f9a1110c48065174897c92de441f45e7a"},"posted_at":"2026-06-29T17:43:16.338Z","created_at":"2026-06-29T17:43:16.338Z","updated_at":"2026-07-17T02:41:16.988Z","machine":{"shape":"article.machine/v1","slug":"retatrutide-glp1-agonists","kind":"article","read":{"human":"https://miscsubjects.com/a/retatrutide-glp1-agonists","json":"https://miscsubjects.com/api/articles/retatrutide-glp1-agonists","bundle":"https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":1,"sources":22,"contributions":4,"revisions":3,"objections_url":"https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=retatrutide-glp1-agonists","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-glp1-agonists\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-glp1-agonists\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"retatrutide-glp1-agonists\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/retatrutide-glp1-agonists | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/retatrutide-glp1-agonists","json":"/api/articles/retatrutide-glp1-agonists","markdown":"/api/articles/retatrutide-glp1-agonists/bundle?format=markdown","skill":"/api/articles/retatrutide-glp1-agonists/skill","topology":"/api/articles/retatrutide-glp1-agonists/topology","versions":"/api/articles/retatrutide-glp1-agonists/revisions","invocations":"/api/articles/retatrutide-glp1-agonists/invocations"},"editorial_review":null,"editorial_audit":{"slug":"retatrutide-glp1-agonists","ok":false,"issues":[{"code":"heading_filing_label","message":"section heading “Overview” is a filing label that gives a cold reader no claim","replacement":"Replace “Overview” with the concrete claim, event, or object introduced in that section."},{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"dcd6b7bdb3704e6e308dd7c9e774bd45269f7b4d7d44b04b150e3024d021c061"}}}